Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.10, read 2026-11-02
Ethical does not pass the values gate
Price17.13 USD
Fair value18.60
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-11-03Read Markup18.37-6.8% to today Distribution gives way to Markup after a 12% rise in 2 weeks
2026-10-17Read Distribution16.42+4.3% to today Markup gives way to Distribution after a 10% rise in 6 weeks
2026-09-05Read Markup14.90+15.0% to today ✓Distribution gives way to Markup after a 10% slide in 9 weeks
2026-07-02Read Distribution16.56+3.4% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Mirion Technologies, Inc. holds its Markup at $17.13. Consolidating, no directional conviction, held for 45 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 45 days
Price at the screen
$17.13
Valuation
163.36 trailing · 27.22 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.07
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
34.38%
Below 33%
Interest-bearing debt is 34.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.19%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
16.55%
Below 49%
Money owed to the company is 16.6% of assets, under the 49% limit.
Pass
Revenue purity
1.31%
Below 5%
Only 1.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Mirion Technologies,'s business is in a permissible area, but its interest-bearing debt is about 34% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MIR's ethical verdict changes
Today MIR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly an 8% discount to our $18.60 fair value, 24.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 7.9% discount to the base estimate.
Where our models see it going: fair-value estimate $18.60, with a range of $18.00 to $21.39, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Radiation Tools Maker Fails to Clear Our Bar
When a hospital runs its scanners or a reactor tracks stray particles, Mirion sits behind the scenes supplying the sensors. Revenue is rising fast at 28 percent, yet the business converts barely 3 percent of sales into profit and returns just 2 percent on equity. That leaves a forward multiple of 24 times earnings sitting on thin returns and an unknown competitive edge, which is why the opportunity rating stays at none despite the ethical pass.
Analysts see upside to 28 dollars and a strong buy rating, but the numbers show a company still scaling without clear pricing power or durable margins. The 29 percent gap to our fair value looks attractive on paper, yet low returns on capital and limited visibility into a real moat keep us on the sidelines.
Currency swings, regulatory delays in nuclear projects, and execution risk around medical segment growth all sit in the open. The setup rewards patience only if profitability improves sharply from here. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MIR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup · changed$18.37+20.5%Entry 16
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28.
2026-10-27Distribution$15.24+0.0%Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Distribution$15.24+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$15.24+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Distribution$15.24+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Distribution$15.24+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Distribution$15.24+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Distribution$15.24-7.2%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Distribution$16.42+0.0%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 14.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it strong buy, with a mean price target of $28.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
